drugset
drugset / Trial / NCT01382589

Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo

NCT01382589 ↗

Phase 2 Completed 15 enrolled Clinuvel Pharmaceuticals Limited
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether afamelanotide and narrow band UVB are effective in the treatment of non-segmental vitiligo (NSV).

Timeline

Start
2011-09
Primary completion
2012-07
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Afamelanotide Peptide 16 mg Subcutaneous

Indications

vitiligo